CN Patent

CN111171019A — 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Assigned to Shanghai Ennovabio Pharmaceuticals Co Ltd · Expires 2020-05-19 · 6y expired

What this patent protects

本发明提供了一类五元并六元杂环化合物的制备和应用，具体地，本发明提供了一类如下式I所示的化合物，其中，各基团的定义如说明书中所述。所述的化合物具有TRK激酶抑制活性，可以作为治疗TRK功能异常相关疾病的药物组合物。

USPTO Abstract

本发明提供了一类五元并六元杂环化合物的制备和应用，具体地，本发明提供了一类如下式I所示的化合物，其中，各基团的定义如说明书中所述。所述的化合物具有TRK激酶抑制活性，可以作为治疗TRK功能异常相关疾病的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN111171019A
Jurisdiction
CN
Classification
—
Expires
2020-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Ennovabio Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.